July 12 (Reuters) - AstraZeneca PLC AZN.L :
* HEALTH CANADA APPROVES TAGRISSO® (OSIMERTINIB) AS FIRST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CANCER
* ASTRAZENECA - HEALTH CANADA APPROVED TAGRISSOFOR FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, OR METASTATIC NON-SMALL CELL LUNG CANCER